Literature DB >> 22617794

Toward a siRNA-containing nanoparticle targeted to breast cancer cells and the tumor microenvironment.

Lígia C Gomes-da-Silva1, Adriana O Santos, Luís M Bimbo, Vera Moura, José S Ramalho, Maria C Pedroso de Lima, Sérgio Simões, João N Moreira.   

Abstract

The present work aimed at designing a lipid-based nanocarrier for siRNA delivery toward two cell sub-populations within breast tumors, the cancer and the endothelial cells from angiogenic tumor blood vessels. To achieve such goal, the F3 peptide, which is specifically internalized by nucleolin overexpressed on both those sub-populations, was used as a targeting moiety. The developed F3-targeted stable nucleic acid lipid particles presented adequate features for systemic administration. In addition, the attachment of the F3 peptide onto the liposomal surface enabled an internalization by both cancer and endothelial cells from angiogenic blood vessels that was significantly higher than the one observed with non-cancer cells. Sequence-specific downregulation of enhanced green fluorescent protein (eGFP) in eGFP-overexpressing human cancer cell lines, both at the protein and mRNA levels, was further observed upon delivery of anti-eGFP siRNA by F3-targeted liposomes, in contrast with the non-targeted counterpart. This effect was highly dependent on the content of poly(ethylene glycol) (PEG), as evidenced by the co-localization studies between the siRNA and the lysosomes. Overall, the present work represents an important contribution toward a nanoparticle with multi-targeting capabilities in breast cancer, both at the cellular and molecular level.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22617794     DOI: 10.1016/j.ijpharm.2012.05.018

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  14 in total

1.  Mono and dually decorated nanoliposomes for brain targeting, in vitro and in vivo studies.

Authors:  E Markoutsa; K Papadia; A D Giannou; M Spella; A Cagnotto; M Salmona; G T Stathopoulos; S G Antimisiaris
Journal:  Pharm Res       Date:  2013-12-13       Impact factor: 4.200

Review 2.  Non-viral nanocarriers for siRNA delivery in breast cancer.

Authors:  Jing Zhang; Xiang Li; Leaf Huang
Journal:  J Control Release       Date:  2014-05-27       Impact factor: 9.776

Review 3.  Stimuli-responsive cross-linked micelles for on-demand drug delivery against cancers.

Authors:  Yuanpei Li; Kai Xiao; Wei Zhu; Wenbin Deng; Kit S Lam
Journal:  Adv Drug Deliv Rev       Date:  2013-09-21       Impact factor: 15.470

Review 4.  Systemic tumor-specific gene delivery.

Authors:  Max Kullberg; Ryan McCarthy; Thomas J Anchordoquy
Journal:  J Control Release       Date:  2013-09-11       Impact factor: 9.776

Review 5.  Challenging the future of siRNA therapeutics against cancer: the crucial role of nanotechnology.

Authors:  Lígia Catarina Gomes-da-Silva; Sérgio Simões; João Nuno Moreira
Journal:  Cell Mol Life Sci       Date:  2013-11-13       Impact factor: 9.261

Review 6.  Nanopreparations to overcome multidrug resistance in cancer.

Authors:  Niravkumar R Patel; Bhushan S Pattni; Abraham H Abouzeid; Vladimir P Torchilin
Journal:  Adv Drug Deliv Rev       Date:  2013-08-23       Impact factor: 15.470

Review 7.  Antisense therapeutics in oncology: current status.

Authors:  Ammad Ahmad Farooqi; Zia Ur Rehman; Jordi Muntane
Journal:  Onco Targets Ther       Date:  2014-11-03       Impact factor: 4.147

8.  Design, synthesis and evaluation of VEGF-siRNA/CRS as a novel vector for gene delivery.

Authors:  Wen Zhao; Yifan Zhang; Xueyun Jiang; Chunying Cui
Journal:  Drug Des Devel Ther       Date:  2016-11-24       Impact factor: 4.162

9.  Tumor-targeted Chlorotoxin-coupled Nanoparticles for Nucleic Acid Delivery to Glioblastoma Cells: A Promising System for Glioblastoma Treatment.

Authors:  Pedro M Costa; Ana L Cardoso; Liliana S Mendonça; Angelo Serani; Carlos Custódia; Mariana Conceição; Sérgio Simões; João N Moreira; Luís Pereira de Almeida; Maria C Pedroso de Lima
Journal:  Mol Ther Nucleic Acids       Date:  2013-06-18       Impact factor: 10.183

Review 10.  Targeted Delivery of siRNA Therapeutics to Malignant Tumors.

Authors:  Qixin Leng; Martin C Woodle; A James Mixson
Journal:  J Drug Deliv       Date:  2017-11-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.